Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None20222021202020192018201720162015 Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021 Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021 Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021 Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 11/03/2021 Poseida Therapeutics Announces Leadership Appointments 10/13/2021 Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021 Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 1 - 10 of 84
Year None20222021202020192018201720162015 Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021 Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021 Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021 Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 11/03/2021 Poseida Therapeutics Announces Leadership Appointments 10/13/2021 Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021 Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 1 - 10 of 84
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen 01/10/2022
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors 12/20/2021
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting 12/13/2021
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 11/09/2021
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting 11/09/2021
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies 10/12/2021
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting 10/01/2021